Status:

COMPLETED

CONTAIN COVID-19: Convalescent Plasma to Limit COVID-19 Complications in Hospitalized Patients

Lead Sponsor:

NYU Langone Health

Collaborating Sponsors:

National Center for Advancing Translational Sciences (NCATS)

Albert Einstein College of Medicine

Conditions:

COVID-19

Coronavirus

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

This is a randomized, blinded phase 2 trial that will assess the efficacy and safety of anti-SARS-CoV-2 convalescent plasma in hospitalized patients with acute respiratory symptoms requiring oxygen su...

Detailed Description

A total of 300 eligible subjects will be randomized in a 1:1 ratio to receive either convalescent plasma (CP) from people who have recovered from COVID-19 containing antibodies to SARS-CoV-2 or a plac...

Eligibility Criteria

Inclusion

  • Inclusion Criteria
  • Patients ≥18 years of age
  • Hospitalized with laboratory confirmed COVID-19
  • One or more of the following respiratory signs or symptoms: cough, chest pain, shortness of breath, fever, oxygen saturation ≤ 94%, abnormal CXR/CT imaging)
  • Hospitalized for ≤ 72 hours OR within day 3 to 7 days from first signs of illness
  • On supplemental oxygen, non-invasive ventilation or high-flow oxygen
  • Patients may be on other randomized controlled trials of pharmaceuticals for COVID -19 and patients who meet eligibility criteria will not be excluded on this basis.
  • Exclusion Criteria
  • Receipt of pooled immunoglobulin in past 30 days
  • Contraindication to transfusion or history of prior reactions to transfusion blood products
  • Invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO)
  • Volume overload secondary to congestive heart failure or renal failure
  • Unlikely to survive past 72 hours from screening based on the assessment of the investigator
  • Unlikely to be able to assess and follow outcome due to poor functional status

Exclusion

    Key Trial Info

    Start Date :

    April 17 2020

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    December 12 2022

    Estimated Enrollment :

    941 Patients enrolled

    Trial Details

    Trial ID

    NCT04364737

    Start Date

    April 17 2020

    End Date

    December 12 2022

    Last Update

    January 26 2023

    Active Locations (9)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 3 (9 locations)

    1

    Yale University School of Medicine

    New Haven, Connecticut, United States, 06520

    2

    University of Miami Hospital and Clinics

    Miami, Florida, United States, 33136

    3

    NYU Langone Health

    New York, New York, United States, 10003

    4

    Montefiore Medical Center

    The Bronx, New York, United States, 10467